Q-omics provides the consensus-scored CYP26C1 profile across patient tissues and cancer cell-line models. CYP26C1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CYP26C1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, CYP26C1 RNA expression shows 13,121 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where CYP26C1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP26C1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP26C1 survival associations across molecular data types. CYP26C1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP26C1 RNA expression–survival associations across cancer types. High CYP26C1 expression shows unfavorable associations in BLCA, READ, UVM and KIRC, but favorable associations in HNSC and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CYP26C1 RNA expression.
This table summarizes CYP26C1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYP26C1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP26C1 shows higher tumor expression in THCA, HNSC, BRCA, STAD, LIHC and LUAD. The THCA box plot shows higher CYP26C1 RNA expression in tumor versus normal tissue (log2 FC = +0.190, t-test p < 0.001).
This table shows molecular features associated with CYP26C1 in patient tissues and cancer cell lines. In patient samples, CYP26C1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP26C1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
